The quarter beat the published bar by a wide margin. The published consensus was approximately $1.02 of EPS and $147.7 million of revenue; Centrus delivered $1.77 of diluted adjusted EPS and $176.1 million of revenue.
| Metric | Q2 2026 actual | Published expectation | Q2 2025 | Read |
|---|---|---|---|---|
| Revenue | $176.1M (Financial Highlights) | ~$147.7M | $154.5M (Financial Highlights) | ~19% above consensus; 14% year over year |
| Adjusted diluted EPS | $1.77 (Adjusted results reconciliation) | ~$1.02 | $1.90 (Adjusted results reconciliation) | ~74% above consensus; down year over year |
| GAAP diluted EPS | $0.77 (Income Statement) | — | $1.59 (Income Statement) | Down 52% year over year |
| Operating cash flow | $(16.7)M (Cash Flow statement) | — | $89.3M (Cash Flow statement) | Cash conversion weakened materially |
| Capital expenditures | $94.8M (Cash Flow statement) | — | $5.7M (Cash Flow statement) | Expansion investment accelerated |
The beat came from revenue timing and a favorable earnings mix, not broad operating improvement. LEU revenue rose 22% to $153.4 million, helped by $53.4 million of new uranium revenue, while SWU revenue fell $25.7 million as volume sold dropped 23%; the average SWU price rose only 3% (Segment results — LEU). That makes the headline revenue beat strong, but less evidence of a clean, volume-driven acceleration.
Underlying profitability was weaker than the adjusted EPS headline suggests. Gross profit fell to $49.9 million from $53.9 million, operating income dropped to $10.4 million from $33.5 million, and adjusted operating income declined to $38.7 million from $40.8 million (Financial Highlights; Adjusted results reconciliation). The company excluded $10.6 million of growth costs and $17.7 million of stock-based compensation from adjusted operating income; those costs are economically relevant while Centrus is still funding its enrichment buildout.
The strategic backlog improved, but its quality is mixed. Total backlog reached $4.5 billion through 2040, including approximately $3.7 billion in LEU backlog and $3.0 billion of contingent LEU/HALEU commitments; $2.4 billion of those contingent commitments are under definitive agreements (Backlog). This supports the long-term expansion thesis, but contingent commitments depend on operational milestones rather than representing fully locked-in revenue.
DOE exposure is the clearest newly visible offset. Approximately $0.8 billion of Technical Solutions backlog relates to the HALEU operating contract, while the proposed fiscal 2027 DOE budget includes no further funding for that cascade and DOE does not currently intend to exercise additional options (Backlog). Technical Solutions already swung to a $1.7 million gross loss from a $3.2 million profit, so the government-contract risk is showing up in current results rather than being purely theoretical (Segment results — Technical Solutions).
Net read: clearly better than consensus, but with lower-quality earnings and heavier execution demands. The large adjusted EPS and revenue beat is the dominant near-term change. However, GAAP profitability, operating cash flow, and technical-solutions economics deteriorated as Centrus spent heavily on centrifuge expansion; cash remained substantial at $1.9 billion, but first-half capital spending was $94.8 million and operating cash flow was negative $16.7 million (Cash Flow statement; Balance Sheet).
Read the original 8-K on SEC EDGAR ↗